Belzutifan beneficial for advanced clear cell renal cell carcinoma patients who had previously received immune checkpoint, antiangiogenic therapies<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Aug. 23, 2024 (HealthDay News) — Belzutifan, a hypoxia-inducible factor 2\u00ce\u00b1 (HIF-2\u00ce\u00b1) inhibitor, improves progression-free survival and objective responses over everolimus among patients with advanced clear-cell renal cell carcinoma, according to a study published in the Aug. 22 issue of the New England Journal of Medicine<\/em>.<\/p>\n Toni K. Choueiri, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues conducted a phase 3 multicenter trial involving participants with advanced clear-cell renal cell carcinoma who had previously received immune checkpoint and antiangiogenic therapies. Participants were randomly assigned to receive 120 mg belzutifan (374 participants) or 10 mg everolimus (372 participants).<\/p>\n The researchers found that median progression-free survival was 5.6 months in both groups at the first interim analysis (median follow-up, 18.4 months); at 18 months, 24.0 and 8.3 percent of participants in the belzutifan and everolimus groups, respectively, were alive and free of progression (two-sided P = 0.002, which met the prespecified significance criterion). A confirmed objective response occurred in 21.9 and 3.5 percent, respectively (P < 0.001, which met the prespecified criterion for significance). Median overall survival was 21.4 and 18.1 months in the belzutifan and everolimus groups, respectively, at the second interim analysis (median follow-up, 25.7 months); at 18 months, 55.2 and 50.6 percent of participants, respectively, were alive (hazard ratio for death, 0.88; 95 percent confidence interval, 0.73 to 1.07; two-sided P = 0.20, which did not meet prespecified significance criterion).<\/p>\n “The LITESPARK-005 trial introduced HIF-2\u00ce\u00b1 inhibition as an active therapeutic mechanism and established belzutifan as a treatment option in patients with advanced renal-cell carcinoma after both immune checkpoint and antiangiogenic therapies,” the authors write.<\/p>\n The study was funded by Merck, the manufacturer of belzutifan.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n